Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform

Alloy Therapeutics, Inc. announced a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited to develop Takeda’s proprietary iPSC derived CAR-T cell platform and iPSC-derived CAR-NK platform.